EA005248B1 - Способ отрицательной регуляции активности gdf-8 - Google Patents

Способ отрицательной регуляции активности gdf-8 Download PDF

Info

Publication number
EA005248B1
EA005248B1 EA200200182A EA200200182A EA005248B1 EA 005248 B1 EA005248 B1 EA 005248B1 EA 200200182 A EA200200182 A EA 200200182A EA 200200182 A EA200200182 A EA 200200182A EA 005248 B1 EA005248 B1 EA 005248B1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide
gdf
epitope
analogue
see
Prior art date
Application number
EA200200182A
Other languages
English (en)
Russian (ru)
Other versions
EA200200182A1 (ru
Inventor
Торбен Халькиер
Серен Моуритсен
Стеен Клюснер
Original Assignee
Фармекса А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармекса А/С filed Critical Фармекса А/С
Publication of EA200200182A1 publication Critical patent/EA200200182A1/ru
Publication of EA005248B1 publication Critical patent/EA005248B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Eletrric Generators (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EA200200182A 1999-07-20 2000-07-20 Способ отрицательной регуляции активности gdf-8 EA005248B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199901014 1999-07-20
US14527599P 1999-07-26 1999-07-26
PCT/DK2000/000413 WO2001005820A2 (en) 1999-07-20 2000-07-20 Method for down-regulating gdf-8 activity

Publications (2)

Publication Number Publication Date
EA200200182A1 EA200200182A1 (ru) 2002-06-27
EA005248B1 true EA005248B1 (ru) 2004-12-30

Family

ID=26065065

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200182A EA005248B1 (ru) 1999-07-20 2000-07-20 Способ отрицательной регуляции активности gdf-8

Country Status (21)

Country Link
US (2) US7056512B1 (cg-RX-API-DMAC7.html)
EP (1) EP1200119A2 (cg-RX-API-DMAC7.html)
JP (1) JP2003506325A (cg-RX-API-DMAC7.html)
KR (1) KR100750695B1 (cg-RX-API-DMAC7.html)
CN (1) CN1384757A (cg-RX-API-DMAC7.html)
AU (1) AU778470B2 (cg-RX-API-DMAC7.html)
CA (1) CA2379852A1 (cg-RX-API-DMAC7.html)
EA (1) EA005248B1 (cg-RX-API-DMAC7.html)
EE (1) EE200200025A (cg-RX-API-DMAC7.html)
HK (1) HK1048937A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20010900A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0201861A3 (cg-RX-API-DMAC7.html)
IL (1) IL146845A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01013232A (cg-RX-API-DMAC7.html)
NO (1) NO20016252L (cg-RX-API-DMAC7.html)
NZ (1) NZ517058A (cg-RX-API-DMAC7.html)
PL (1) PL353855A1 (cg-RX-API-DMAC7.html)
SK (1) SK722002A3 (cg-RX-API-DMAC7.html)
TR (2) TR200400621T2 (cg-RX-API-DMAC7.html)
WO (1) WO2001005820A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200109901B (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ グループ リミテッド ワクチン
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
ITMI20071072A1 (it) 2007-05-25 2008-11-26 Lps Electronics S R L Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa.
WO2005066204A2 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
CA2582940A1 (en) 2004-09-30 2006-04-06 Orico Limited Myostatin isoform
US7888486B2 (en) 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
BRPI0715072A2 (pt) 2006-08-03 2013-06-25 Orico Ltd antagonistas de miostatina
CN100450545C (zh) * 2006-08-03 2009-01-14 中国医学科学院基础医学研究所 肌肉生长抑制素在制备抗肿瘤药物中的应用
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US20140223592A1 (en) * 2011-07-06 2014-08-07 Pig Myostatin Gene Locus And Uses Thereof Pig myostatin gene locus and uses thereof
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
EP4678239A3 (en) 2012-08-01 2026-04-08 Ikaika Therapeutics, Inc. Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
IL276921B2 (en) 2018-03-01 2025-12-01 Regeneron Pharma Methods for altering body composition
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US20240366760A1 (en) * 2023-01-17 2024-11-07 Regen BioPharma, Inc. Activation of survivin-specific immune responses using dendritic cell derived exosomes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
NZ337955A (en) 1997-04-15 2000-09-29 Ferring Farma Lab Modified TNF-alpha and their use as vaccines
WO1999002667A1 (en) 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
EP1038016A2 (en) * 1997-12-16 2000-09-27 Valentis Inc. Needle-free injection of formulated nucleic acid molecules
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers

Also Published As

Publication number Publication date
ZA200109901B (en) 2003-05-28
KR20020026544A (ko) 2002-04-10
KR100750695B1 (ko) 2007-08-22
EP1200119A2 (en) 2002-05-02
MXPA01013232A (es) 2005-05-24
AU778470B2 (en) 2004-12-09
AU5967500A (en) 2001-02-05
NZ517058A (en) 2004-04-30
HUP0201861A2 (en) 2002-09-28
SK722002A3 (en) 2003-02-04
WO2001005820A3 (en) 2001-07-19
NO20016252L (no) 2002-03-15
HUP0201861A3 (en) 2004-07-28
JP2003506325A (ja) 2003-02-18
US7070784B1 (en) 2006-07-04
TR200400621T2 (tr) 2004-08-23
HK1048937A1 (zh) 2003-04-25
PL353855A1 (en) 2003-12-01
IL146845A0 (en) 2002-07-25
NO20016252D0 (no) 2001-12-19
US7056512B1 (en) 2006-06-06
TR200200133T2 (tr) 2002-05-21
CA2379852A1 (en) 2001-01-25
HRP20010900A2 (en) 2003-08-31
WO2001005820A2 (en) 2001-01-25
CN1384757A (zh) 2002-12-11
EE200200025A (et) 2003-04-15
EA200200182A1 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
US7070784B1 (en) Method for down-regulating GDF-8 activity using immunogenic GDF-8 analogues
CA2687533C (en) Immunological methods to modulate myostatin in vertebrate subjects
EA007533B1 (ru) Способ понижающей регуляции белка-предшественника амилоида
HRP20010188A2 (en) Method for down-regulating osteoprotegerin ligand activity
US20040037840A1 (en) Novel therapeutic vaccine formulations
AU2002233166B2 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
WO2004024183A1 (en) Immunization against autologous ghrelin
US11969465B2 (en) Toxoplasma gondii vaccines and their use
AU2002233166A1 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
AU2006228872A1 (en) Immunogenic EGFR peptides comprising foreign Tcell stimulating epitope
CN1921883A (zh) 包含血管动蛋白或编码血管动蛋白的多核苷酸的疫苗及其在治疗血管生成相关紊乱中的用途
AU770409B2 (en) Methods of raising animals for meat production
ZA200502927B (en) Single chain recombinant T cell receptors.
KR20050052499A (ko) 자가 그렐린에 대한 면역화
Kandimalla et al. Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU